Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI falls 43.7% from a year ago
Accumulated OCI stood at $246K at the end of Q1 FY2026, down 43.7% from a year earlier and down 62.3% from the prior quarter.
Context
- Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -43.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 652K USD
- Year-over-year change
- +1616.3%
- 4-year CAGR
- +260159.7%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 652K | +1616.3% |
| FY2024 | 2024-12-31 | (43K) | -122.1% |
| FY2023 | 2023-12-31 | 195K | +109.5% |
| FY2022 | 2022-12-31 | (2.06M) | -14474850677345584.0% |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's Mar 2026 Accumulated OCI of $246K is the highest of the 11 companies compared; the peer median is -$48.5K.
- Its year-over-year change of -43.7% is the 2nd highest of 8, against a peer median of -93.4%.
- Accumulated OCI amounts to 0.1% of total assets for TRDA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $246K | -43.7% | — | 0.1% | |
| Mar 2026 | $212K | -44.6% | — | 0.0% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $8K | -93.4% | — | 0.0% |
| Mar 2026 | $2K | -66.7% | +35.7% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$97K | -182.2% | — | 0.0% | |
| Mar 2026 | -$183K | -525.6% | — | 0.0% | |
| Mar 2026 | -$253.73K | -114.0% | +39.1% | 0.1% | |
| Mar 2026 | -$263K | -32.2% | — | 0.1% | |
| Mar 2026 | -$241.01M | — | — | 0.1% | |
| Peer median (excluding TRDA) | -$48.5K | -93.4% | +37.4% | 0.0% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291.06M | 45.16M | 67.6M | 101.21M | 90.39M |
| Short-term Investments | 0 | 143.56M | 284.37M | 318.79M | 205.3M |
| Net Receivables | 0 | 0 | 5.88M | 3.68M | 2.58M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 21.16M | 11.92M | 16.36M | 7.98M |
| Total Current Assets | 298.7M | 209.88M | 369.77M | 440.04M | 306.25M |
| Property, Plant & Equipment (Net) | 6.26M | 33.02M | 92.68M | 82.05M | 67.76M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 872K | 9.16M | 6.74M | 4.23M | 3.36M |
| Total Non-current Assets | 7.13M | 42.18M | 99.42M | 86.28M | 71.13M |
| Total Assets | 305.83M | 252.06M | 469.19M | 526.32M | 377.38M |
| Account Payables | 706K | 5.99M | 3.28M | 4.26M | 2.29M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 4.02M | 667K | 0 |
| Deferred Revenue | 0 | 0 | 132.26M | 13.65M | 342K |
| Other Current Liabilities | 4.56M | 5.49M | 7.66M | 8.43M | 9.22M |
| Total Current Liabilities | 6.72M | 21.97M | 158.8M | 39.48M | 24.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 7.72M | 6.51M | 0 |
| Other Non-current Liabilities | 396K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 396K | 17.53M | 68.04M | 58.16M | 46.79M |
| Total Liabilities | 7.12M | 39.5M | 226.83M | 97.64M | 71.25M |
| Common Stock | 3K | 3K | 3K | 4K | 4K |
| Retained Earnings | (93.67M) | (188.29M) | (194.97M) | (129.34M) | (273.09M) |
| Accumulated OCI | 0 | (2.06M) | 195K | (43K) | 652K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 298.72M | 212.55M | 242.36M | 428.68M | 306.13M |
| Total Debt | 0 | 25.94M | 68.23M | 59.21M | 50.93M |
| Net Debt | (291.06M) | (19.22M) | 628K | (42M) | (39.46M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.